论文信息 - Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. - 字舞流文

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

R. Kerbel | R. Wells | Y. Shaked | Christina R. Lee | R. Buckstein | M. Cheung | A. Mamedov | M. Reis | Liying Zhang | A. Chesney | M. Lenis | L. Chodirker | Mary-Anne Cussen | C. Davidson